Glaxo sells drugs rights to Novartis in $1bn deal

GlaxoSmithKline has agreed a deal worth up to $1bn to sell the rights for the use of a drug in a range of illnesses that can include multiple sclerosis.

The deal with Novartis follows a previous series of asset swaps between the two companies that completed earlier this year.